Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).

Journal:
Journal of Clinical Oncology
Published:
DOI:
10.1200/jco-25-01969
Affiliations:
5
Authors:
19
Go to article
Institutions Authors Share
Haihe Laboratory of Cell Ecosystem, China
8.166667
 0.43
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), China
7.666667
 0.40
YaKe Biotech, China
2.000000
 0.11
Beijing GoBroad Boren Hospital, China
0.666667
 0.04
School of Life Sciences, Fudan University, China
0.500000
 0.03
Interested in Oncology and Carcinogenesis?